Sol-Gel Technologies Hosts KOL Investor Event on SGT-610

NESS ZIONA, Israel, Sept. 30, 2026 /CourierPR/ -- Sol-Gel Technologies, a dermatology company pioneering treatments for rare and severe skin conditions, is set to host a Key Opinion Leader (KOL) Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026, in New York. The event will feature a panel of experts discussing the significant disease burden of Gorlin Syndrome patients and the lack of effective therapies currently available.

The KOLs participating in the event include Julie Breneiser, PA-C, the Associate Director of the Gorlin Syndrome Alliance; Ervin Epstein Jr., MD, a dermatologist with over 50 years of experience in the San Francisco Bay Area; Kavita Sarin, MD, PhD, a Professor of Dermatology and Director of the Stanford Skin Cancer Genetics Program; and Elizabeth M. Billingsley, MD, FAAD, FACMS, FASDS, a Professor of Dermatology at Penn State University College of Medicine.

Julie Breneiser, PA-C, will provide insights into the collaboration with industry to bring potential treatments to clinical trial. Dr. Ervin Epstein Jr., MD, will share his extensive research background, focusing on the molecular biology of inherited and neoplastic skin diseases. Dr. Kavita Sarin, MD, PhD, will discuss the integration of genetic and clinical patient data to inform susceptibility, prognosis, and treatments in skin cancer and other rare dermatologic disorders. Dr. Elizabeth M. Billingsley, MD, FAAD, FACMS, FASDS, will present on the surgical management of skin cancer and her clinical research in Gorlin Syndrome.

Sol-Gel Technologies is advancing SGT-610, a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin Syndrome. The company is also developing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need.

Forward-looking statements in the press release are based on information available to the company when the statements were made or on its management's current expectations. The company cautions that actual results may differ materially from those indicated by the forward-looking statements due to various risks and uncertainties, including the potential delay in reporting the top-line results of Sol-Gel’s pivotal Phase 3 clinical trial of SGT-610 and the possibility of the trial failing to meet its primary endpoint or one or more of its secondary endpoints.